Achievement of LDL-C Targets Defined by ESC/EAS (2011) Guidelines in Risk-Stratified Korean Patients with Dyslipidemia Receiving Lipid-Modifying Treatments.
Adult
Aged
Biomarkers
/ blood
Cholesterol, LDL
/ blood
Cross-Sectional Studies
Dyslipidemias
/ blood
Female
Follow-Up Studies
Humans
Hydroxymethylglutaryl-CoA Reductase Inhibitors
/ therapeutic use
Male
Middle Aged
Practice Guidelines as Topic
/ standards
Prognosis
Republic of Korea
/ epidemiology
Risk Assessment
/ methods
Cholesterol, LDL
Hydroxymethylglutaryl-CoA reductase inhibitors
Korea
Practice guideline
Risk assessment
Dyslipidemias
Journal
Endocrinology and metabolism (Seoul, Korea)
ISSN: 2093-5978
Titre abrégé: Endocrinol Metab (Seoul)
Pays: Korea (South)
ID NLM: 101554139
Informations de publication
Date de publication:
06 2020
06 2020
Historique:
received:
16
12
2019
accepted:
14
04
2020
entrez:
4
7
2020
pubmed:
4
7
2020
medline:
12
6
2021
Statut:
ppublish
Résumé
This study assessed the proportion of risk-stratified Korean patients with dyslipidemia achieving their low-density lipoprotein cholesterol (LDL-C) targets as defined by the European Society of Cardiology/European Atherosclerosis Society (ESC/EAS) (2011) guidelines while receiving lipid-modifying treatments (LMTs). In this multicenter, cross-sectional, observational study, we evaluated data from Korean patients aged ≥19 years who were receiving LMTs for ≥3 months and had an LDL-C value within the previous 12 months on the same LMT. Data were collected for demographics, cardiovascular (CV) risk factors, medical history, and healthcare consumption. Patients were risk-stratified according to the ESC Systematic COronary Risk Evaluation (SCORE) chart and LDL-C target achievement rate was assessed. Guideline-based risk-stratification of the 1,034 patients showed the majority (72.2%) to be in the very high-risk category. Investigators' assessment of risk was underestimated in 71.6% compared to ESC/EAS guidelines. Overall LDL-C target achievement rate was 44.3%; target achievement was the highest (66.0%) in moderate-risk patients and the lowest (39.0%) in very high-risk patients. Overall 97.1% patients were receiving statin therapy, mostly as a single-agent (89.2%). High-intensity statins and the highest permissible dose of high-intensity statins had been prescribed to only 9.1% and 7.3% patients in the very high-risk group, respectively. Physician satisfaction with patients' LDL-C levels was the primary reason for non-intensification of statin therapy. Achievement of target LDL-C level is suboptimal in Korean patients with dyslipidemia, especially in those at very high-risk of CV events. Current practices in LMTs need to be improved based on precise CV risk evaluation posed by dyslipidemia.
Sections du résumé
BACKGROUND
This study assessed the proportion of risk-stratified Korean patients with dyslipidemia achieving their low-density lipoprotein cholesterol (LDL-C) targets as defined by the European Society of Cardiology/European Atherosclerosis Society (ESC/EAS) (2011) guidelines while receiving lipid-modifying treatments (LMTs).
METHODS
In this multicenter, cross-sectional, observational study, we evaluated data from Korean patients aged ≥19 years who were receiving LMTs for ≥3 months and had an LDL-C value within the previous 12 months on the same LMT. Data were collected for demographics, cardiovascular (CV) risk factors, medical history, and healthcare consumption. Patients were risk-stratified according to the ESC Systematic COronary Risk Evaluation (SCORE) chart and LDL-C target achievement rate was assessed.
RESULTS
Guideline-based risk-stratification of the 1,034 patients showed the majority (72.2%) to be in the very high-risk category. Investigators' assessment of risk was underestimated in 71.6% compared to ESC/EAS guidelines. Overall LDL-C target achievement rate was 44.3%; target achievement was the highest (66.0%) in moderate-risk patients and the lowest (39.0%) in very high-risk patients. Overall 97.1% patients were receiving statin therapy, mostly as a single-agent (89.2%). High-intensity statins and the highest permissible dose of high-intensity statins had been prescribed to only 9.1% and 7.3% patients in the very high-risk group, respectively. Physician satisfaction with patients' LDL-C levels was the primary reason for non-intensification of statin therapy.
CONCLUSION
Achievement of target LDL-C level is suboptimal in Korean patients with dyslipidemia, especially in those at very high-risk of CV events. Current practices in LMTs need to be improved based on precise CV risk evaluation posed by dyslipidemia.
Identifiants
pubmed: 32615721
pii: EnM.2020.35.2.367
doi: 10.3803/EnM.2020.35.2.367
pmc: PMC7386099
doi:
Substances chimiques
Biomarkers
0
Cholesterol, LDL
0
Hydroxymethylglutaryl-CoA Reductase Inhibitors
0
Types de publication
Journal Article
Multicenter Study
Observational Study
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
367-376Références
Circulation. 1998 May 12;97(18):1837-47
pubmed: 9603539
N Engl J Med. 1998 Nov 5;339(19):1349-57
pubmed: 9841303
Atherosclerosis. 2011 Jul;217(1):3-46
pubmed: 21882396
Eur J Prev Cardiol. 2018 Jul;25(10):1087-1094
pubmed: 29771156
Eur J Prev Cardiol. 2012 Aug;19(4):781-94
pubmed: 21450606
N Engl J Med. 1996 Oct 3;335(14):1001-9
pubmed: 8801446
J Atheroscler Thromb. 2014;21(11):1219-27
pubmed: 25069813
Circulation. 2009 Jul 7;120(1):28-34
pubmed: 19546386
Eur Heart J. 2003 Jun;24(11):987-1003
pubmed: 12788299
Atherosclerosis. 2016 Dec;255:200-209
pubmed: 27667299
J Glob Health. 2017 Dec;7(2):020702
pubmed: 29057073
JAMA. 2001 May 16;285(19):2486-97
pubmed: 11368702
J Clin Lipidol. 2014 Jan-Feb;8(1):29-60
pubmed: 24528685
Circulation. 2001 Sep 4;104(10):1108-13
pubmed: 11535564
Am Heart J. 2017 Nov;193:84-92
pubmed: 29129260
Lancet. 2012 Aug 11;380(9841):581-90
pubmed: 22607822
Korean Circ J. 2012 Feb;42(2):86-94
pubmed: 22396695
World J Diabetes. 2017 Jun 15;8(6):230-234
pubmed: 28694924
J Clin Lipidol. 2015 Mar-Apr;9(2):129-69
pubmed: 25911072
J Atheroscler Thromb. 2016 May 2;23(5):567-87
pubmed: 26632163
Lancet. 1994 Nov 19;344(8934):1383-9
pubmed: 7968073
Diabetes Metab J. 2013 Dec;37(6):433-49
pubmed: 24404515
Eur Heart J. 2016 Oct 14;37(39):2999-3058
pubmed: 27567407
Arterioscler Thromb Vasc Biol. 2000 Mar;20(3):830-5
pubmed: 10712410
J Clin Lipidol. 2016 May-Jun;10(3):528-537.e3
pubmed: 27206940
J Am Coll Cardiol. 2014 Jul 1;63(25 Pt B):2889-934
pubmed: 24239923
Fam Pract. 2011 Oct;28(5):524-31
pubmed: 21566005
Diabetes Metab J. 2011 Dec;35(6):628-36
pubmed: 22247906
Circ Cardiovasc Qual Outcomes. 2012 May;5(3):327-34
pubmed: 22474244
Atherosclerosis. 2010 Dec;213(2):598-603
pubmed: 20947087
Korean Circ J. 2012 Feb;42(2):80-2
pubmed: 22396693
J Korean Med Sci. 2004 Apr;19(2):195-201
pubmed: 15082890